Previous 10 | Next 10 |
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery tech...
Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial Late-breaking data demonstrate that MAT2203 achieves impressive in vivo efficacy and has in vitro killing activity 5 to ...
Matinas BioPharma ( NYSE: MTNB ) appoints current board member, Eric J. Ende, to succeed Herbert J. Conrad as Chairman of the Board, effective October 1, 2022. Mr. Conrad is the founding Chairman of the company will remain on the Board as an independent...
BEDMINSTER, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery tec...
BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced toda...
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2022 Earnings Conference Call August 11, 2022, 8:30 AM ET Company Participants Peter Vozzo - Investor Relations Representative Jerry Jabbour - Chief Executive Officer Dr. Terry Matkovits - Chief Development Officer K...
Matinas Biopharma press release ( NYSE: MTNB ): Q2 GAAP EPS of -$0.03 in-line. Revenue of $1.06M beats by $1M . “The second quarter of 2022 through today has been a period of significant execution for our Company, and especially for our lead, late stage clin...
75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022 FDA Provides Flexibility and Clarity on Phase 3 Program and Single Pivotal Registration Trial for MAT2203 in Cryptococcal Meningitis; Trial Expected ...
BEDMINSTER, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today...
BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technolo...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...